The safety of Cenforce 150 mg, like all medications, is monitored by various stakeholders at different stages:

Pharmaceutical companies: The companies that manufacture Cenforce 150 are responsible for conducting preclinical and clinical trials to evaluate its safety and efficacy before seeking regulatory approval for marketing.

Regulatory authorities: Regulatory agencies such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe are responsible for reviewing the data submitted by pharmaceutical companies and determining whether to approve Cenforce 150 mg for use in their respective jurisdictions. These agencies continue to monitor the safety of approved medications through post-marketing surveillance programs.

Healthcare providers: Physicians, pharmacists, and other healthcare professionals play a crucial role in monitoring the safety of Cenforce 150 mg by prescribing it appropriately, monitoring patient responses, and reporting any adverse effects or concerns to regulatory authorities.

Patients: Patients who use Cenforce 150 mg or any other medication have a responsibility to be informed about its potential risks and benefits, follow their healthcare provider's instructions for use, report any adverse effects or concerns, and seek medical attention if needed.

Medical community: The medical community at large, including researchers, academics, and professional organizations, contributes to monitoring the safety of Cenforce 150 mg by conducting studies, sharing information and best practices, and raising awareness about potential risks and safety considerations.

Overall, ensuring the safety of Cenforce 150 mg is a collaborative effort involving pharmaceutical companies, regulatory authorities, healthcare providers, patients, and the broader medical community. Continuous monitoring and reporting of adverse events help identify potential safety issues and ensure that appropriate measures are taken to protect patient health.